RECRUITINGOBSERVATIONAL
Establishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal Cancer
About This Trial
This study measures the levels of circulating tumor DNA (ctDNA) in patients with stage II-III rectal cancer before, during, and after treatment to find out if the presence or absence of ctDNA in patient's blood using the Signatera test can be used to gauge how different treatments may affect rectal cancer. ctDNA is DNA from the rectal cancer that is circulating in the blood. The purpose of this study is to understand if the way rectal tumors respond to standard treatment can be associated with varying levels of ctDNA.
Who May Be Eligible (Plain English)
Who May Qualify:
- Participant must provide written willing to sign a consent form before any study-specific procedures or interventions are performed
- Participants aged \>= 18 years
- Pathologically-confirmed stage II or III primary adenocarcinoma of the rectum:
- T3N0M0 - T4bN2M0
Who Should NOT Join This Trial:
- Has radiologic evidence of distant metastases at the time of screening/enrollment
- Has received prior treatment for their rectal adenocarcinoma
- Requires or has received blood transfusion within 1 month of study enrollment
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Participant must provide written informed consent before any study-specific procedures or interventions are performed
* Participants aged \>= 18 years
* Pathologically-confirmed stage II or III primary adenocarcinoma of the rectum:
* T3N0M0 - T4bN2M0
Exclusion Criteria:
* Has radiologic evidence of distant metastases at the time of screening/enrollment
* Has received prior treatment for their rectal adenocarcinoma
* Requires or has received blood transfusion within 1 month of study enrollment
Treatments Being Tested
PROCEDURE
Biopsy
Undergo biopsy
PROCEDURE
Biospecimen Collection
Undergo collection of blood and/or tissue samples
OTHER
Electronic Health Record Review
Medical records are reviewed
Locations (2)
OHSU Knight Cancer Institute
Portland, Oregon, United States
Fred Hutch
Seattle, Washington, United States